Bioenterprise Media Strategy 2020: Social Media, Mainstream Coverage, and a New Model of Trust


In 2012 and 2016, the first two strategic science-business media models were published (SBBMM 1.0 and 2.0). Since that time, there have been significant changes both to the media landscape and to the usage and capability of online and social media platforms. This paper seeks to describe the current bioindustry-relevant media landscape, to introduce a new media model, the Strategic Bioenterprise Media Model 2020 (SBMM 2020), which reflects this new landscape, and to present a mainstream submodel to support the latest opportunity for biotechnology media coverage: Mainstream Media. Examples are drawn from media coverage following the FDA approvals of Zulresso from Sage Therapeutics, Aimovig from Novartis and Amgen, and AquAdvantage salmon from AquAdvantage Technologies. The overall goal of this paper is to equip bioenterprise professionals with an understanding of media dynamics and the strategic potential it brings, ultimately contributing to bioenterprise success.

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.